Analysis of chlorthalidone in whole blood by high-performance liquid chromatography

Rosenberg, Marc J.; Lam, K. K.; Dorsey, Thomas E.

doi:10.1016/s0378-4347(00)83740-8

Cited by 10 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were reports of ultraviolet spectroscopy [4], supercritical fluid chromatography [5], gas chromatography [6], reverse phase high-performance liquid chromatography (RP-HPLC) [7], Stability indicating RP-HPLC method [8], simultaneous estimations by RP-HPLC in pharmaceutical formulation [9,10] and biological samples [11,12]. Also stereoselective UFLC [13] method was developed for the same drug by using kromosil TBB (0, 0'-bis (4-tertbutylbenzoyl)-N, N'-diallylLtartardiamide) chiral column but the reported work was based on normal phase method (makes the method more expensive) and the method is less sensitive.…”

Section: Fig 1: Chemical Structure Of Chlorthalidone [4]mentioning

confidence: 99%

Validated Chiral Rp-Uflc Method for the Quantification of Chlorthalidone in Bulk and Pharmaceutical Dosage Form

Choezom

Gurupadayya

2017

Int J App Pharm

View full text Add to dashboard Cite

Objective: Development and validation of new, simple and reliable enantioselective reverse phase ultra-fast liquid chromatography (RP-UFLC) method for quantification of chlorthalidone in bulk and pharmaceutical dosage form. Methods:In the present study, the isocratic RP-UFLC method was developed on Phenomenex ® Lux cellulose 4 column (250×4.6 mm, 5µ) and disodium hydrogen phosphate buffer (pH 3.6): methanol (40:60 v/v) as mobile phase. Elute was monitored at 240 nm with a flow rate of 1 ml/min. Results:The described method provided linear correlation (R 2 =0.999) between the range of 2-10 µg/ml. Chlorthalidone enantiomers showed good resolution with a retention time (tR) of 5.75 min and 7.46 min respectively. The precision of the method revealed that relative standard deviation is within the acceptable limit. The percentage recovery of each chlorthalidone enantiomers was found to be 99.98% and 100.09% respectively. The method was validated in accordance with ICH harmonized tripartite guidelines, validation of analytical procedures: text and methodology Q2 (R1). Conclusion:An economical, accurate, sensitive and precise RP-UFLC method was developed and fully validated for quality control analysis of chlorthalidone in pharmaceutical dosage form.

show abstract

Section: Fig 1: Chemical Structure Of Chlorthalidone [4]mentioning

confidence: 99%

Validated Chiral Rp-Uflc Method for the Quantification of Chlorthalidone in Bulk and Pharmaceutical Dosage Form

Choezom

Gurupadayya

2017

Int J App Pharm

View full text Add to dashboard Cite

show abstract

“…The literature reveals that several methods have been reported for the determination of CAN and CHL individually in biological samples (Fleuren & Van Rossum, ; Forjan, Maričič, Prosen, & Brodnjak, ; Guelen, Baars, Vree, Nijkerk, & Vermeer, ; Lou, Ruan, & Jiang, ; Muirhead & Christie, ; Peepliwal, Bonde, & Mohanraj, ; Rosenberg, Lam, & Dorsey, ; Salado & Vera‐Avila, ; Stenhoff, Lagerström, & Andersen, ; Zhang & Qiang, ). Several analytical methods have been applied to quantify CAN in biological fluids, including HPLC with UV detection (Peepliwal et al, ), HPLC with fluorometric detection (Stenhoff et al, ), LC–MS (Zhang & Qiang, ) and LC–MS/MS methods (Forjan et al, ; Lou et al, ).…”

Section: Introductionmentioning

confidence: 99%

“…However, the listed methods have either higher LLOQ concentration (Peepliwal et al, ; Stenhoff et al, ) and/or comparatively higher run times (Forjan et al, ; Lou et al, ; Zhang & Qiang, ). On the other hand, CHL has been determined in biological matrices by HPLC‐UV (Guelen et al, ; Muirhead & Christie, ; Rosenberg et al, ; Salado & Vera‐Avila, ) and GC‐flame ionization detector (FID) detection (Fleuren & Van Rossum, ). There are several reports for the combination of CAN with drugs other than CHL (Bharathi, Hotha, Chatki, Satyanarayana, & Venkateswarlu, ; Erk, ; Levi, Wuerzner, Ezan, & Pruvost, ) and combination of CHL with drugs other than CAN (Elgawish, Mostafa, & Elshanawaneb, ; Ramakrishna et al, ).…”

Section: Introductionmentioning

confidence: 99%

The simultaneous UPLC–MS/MS determination of emerging drug combination; candesartan and chlorthalidone in human plasma and its application

Patel

Jangid

Suhagia

et al. 2017

Biomedical Chromatography

View full text Add to dashboard Cite

A novel, precise, sensitive and accurate ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method has been developed for the simultaneous determination of a novel drug combination, candesartan (CAN) and chlorthalidone (CHL), in human plasma. Chromatographic separation was achieved on Waters Acquity UPLC BEH C (50 × 2.1 mm, 1.7 μm). Mobile phase consisting of 1 mm ammonium acetate in water-acetonitrile (20:80 v/v) was used. The total chromatographic runtime was 1.9 min with retention times for CAN and CHL at 0.7 and 1.1 min respectively. Ionization and detection of analytes and internal standards was performed on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring and negative ionization mode. Quantitation was done to monitor protonated precursor → product ion transition of m/z 439.2 → 309.0 for CAN, 337.0 → 189.8 for CHL and 443.2 → 312.1 for candesartan D4 and 341.0 → 189.8 for chlorthalidone D4. The method was validated over a wide dynamic concentration range of 2.0-540.0 ng/mL for candesartan and 1.0-180.0 ng/mL for chlorthalidone. The validated method was successfully applied for the assay of CAN and CHL in healthy volunteers.

show abstract

“…), liquid chromatography with UV (Bhatia et al ., ; Chiap et al ., ), fluorescence (Braza et al ., ; Iha et al ., ; Leite et al ., ; Spanakis and Niopas, ; Yilmaz et al ., ) and mass spectrometric detection (D'Orazio and Fanali, ; Johnson and Lewis, ; Lawson et al ., ; Li et al ., ). Similarly, CHL has been determined in human plasma, whole blood and urine by GC with nitrogen detection (Feleuren and Rossum, ) and HPLC‐UV (Guelen et al ., ; Muirhead and Christie, ; Rosenberg et al ., ; Salado and Vera‐Avila, ) methods. A method to determine CHL and celiprolol, a cardioselective β ‐blocker in tablets, human plasma and urine has also been reported (Belal et al ., ).…”

Section: Introductionmentioning

confidence: 99%

Simultaneous quantification of atenolol and chlorthalidone in human plasma by ultra‐performance liquid chromatography–tandem mass spectrometry

Shah

Patel

Shah

et al. 2015

Biomedical Chromatography

View full text Add to dashboard Cite

A simple, sensitive and reproducible ultra-performance liquid chromatography-tandem mass spectrometry method has been developed for the simultaneous determination of atenolol, a β-adrenergic receptor-blocker and chlorthalidone, a monosulfonamyl diuretic in human plasma, using atenolol-d7 and chlorthalidone-d4 as the internal standards (ISs). Following solid-phase extraction on Phenomenex Strata-X cartridges using 100 μL human plasma sample, the analytes and ISs were separated on an Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 µm) column using a mobile phase consisting of 0.1% formic acid-acetonitrile (25:75, v/v). A tandem mass spectrometer equipped with electrospray ionization was used as a detector in the positive ionization mode for both analytes. The linear concentration range was established as 0.50-500 ng/mL for atenolol and 0.25-150 ng/mL for chlorthalidone. Extraction recoveries were within 95-103% and ion suppression/enhancement, expressed as IS-normalized matrix factors, ranged from 0.95 to 1.06 for both the analytes. Intra-batch and inter-batch precision (CV) and accuracy values were 2.37-5.91 and 96.1-103.2%, respectively. Stability of analytes in plasma was evaluated under different conditions, such as bench-top, freeze-thaw, dry and wet extract and long-term. The developed method was superior to the existing methods for the simultaneous determination of atenolol and chlorthalidone in human plasma with respect to the sensitivity, chromatographic analysis time and plasma volume for processing. Further, it was successfully applied to support a bioequivalence study of 50 mg atenolol + 12.5 mg chlorthalidone in 28 healthy Indian subjects.

show abstract

Analysis of chlorthalidone in whole blood by high-performance liquid chromatography

Cited by 10 publications

References 14 publications

Validated Chiral Rp-Uflc Method for the Quantification of Chlorthalidone in Bulk and Pharmaceutical Dosage Form

Validated Chiral Rp-Uflc Method for the Quantification of Chlorthalidone in Bulk and Pharmaceutical Dosage Form

The simultaneous UPLC–MS/MS determination of emerging drug combination; candesartan and chlorthalidone in human plasma and its application

Simultaneous quantification of atenolol and chlorthalidone in human plasma by ultra‐performance liquid chromatography–tandem mass spectrometry

Contact Info

Product

Resources

About